p.111 抽出テキスト
702. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose cotransporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci 2020; 5:632–44. https://doi.org/10.1016/j.jacbts.2020.02.004 703. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776–85. https://doi.org/10.1016/ S2213-8587(19)30249-9 704. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303 705. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383: 1413–24. https://doi.org/10.1056/NEJMoa2022190 706. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61. https://doi.org/10.1056/NEJMoa2107038 707. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089–98. https://doi.org/10.1056/NEJMoa2206286 708. Razuk V, Chiarito M, Cao D, Nicolas J, Pivato CA, Camaj A, et al. SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2022;8:557–67. https://doi.org/10.1093/ehjcvp/pvac001 709. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) wth the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2023;44:3627–39. https://doi.org/10.1093/eurheartj/ehad195 710. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021;385:896–907. https://doi.org/10.1056/NEJMoa2108269 711. Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9:653–62. https://doi.org/10.1016/S2213-8587(21) 00203-5 712. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–31. https://doi.org/10.1056/NEJMoa1707914 713. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752–62. https://doi.org/10.1056/NEJMoa1809798 714. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381: 2497–505. https://doi.org/10.1056/NEJMoa1912388 715. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838–47. https://doi. org/10.1056/NEJMoa2021372 716. Andreis A, Imazio M, Piroli F, Avondo S, Casula M, Paneva E, et al. Efficacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease: a systematic review and meta-analysis on 12 869 patients. Eur J Prev Cardiol 2022;28:1916–25. https://doi.org/10.1093/eurjpc/ zwab045 717. Abdallah MS, Wang K, Magnuson EA, Osnabrugge RL, Kappetein AP, Morice MC, et al. Quality of life after surgery or DES in patients with 3-vessel or left main disease. J Am Coll Cardiol 2017;69:2039–50. https://doi.org/10.1016/j.jacc.2017.02.031 718. Bittl JA, He Y, Jacobs AK, Yancy CW, Normand SLT; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation 2013;127: 2177–85. https://doi.org/10.1161/CIRCULATIONAHA.112.000646 719. Yusuf S, Zucker D, Passamani E, Peduzzi P, Takaro T, Fisher LD, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344:563–70. https://doi.org/10.1016/s0140-6736(94)91963-1 720. Takaro T, Peduzzi P, Detre KM, Hultgren HN, Murphy ML, van der Bel-Kahn J, et al. Survival in subgroups of patients with left main coronary artery disease. Veterans Administration Cooperative Study of surgery for coronary arterial occlusive disease. Circulation 1982;66:14–22. https://doi.org/10.1161/01.cir.66.1.14 721. Talano JV, Scanlon PJ, Meadows WR, Kahn M, Pifarre R, Gunnar RM. Influence of surgery on survival in 145 patients with left main coronary artery disease. Circulation 1975; 52:I105–111. 722. European Coronary Surgery Study Group. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. Lancet 1982;320:1173–80. https://doi.org/10.1016/ S0140-6736(82)91200-4 723. Coronary artery surgery study (CASS). A randomized trial of coronary artery bypass surgery. Survival data. Circulation 1983;68:939–50. https://doi.org/10.1161/01.CIR.68. 5.939 724. Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. New Engl J Med 1984;311:1333–9. https://doi.org/10. 1056/nejm198411223112102 725. Windecker S, Stortecky S, Stefanini GG, daCosta BR, Rutjes AW, Di Nisio M, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ 2014;348:g3859. https://doi.org/10.1136/bmj.g3859 726. Miller RJH, Bonow RO, Gransar H, Park R, Slomka PJ, Friedman JD, et al. Percutaneous or surgical revascularization is associated with survival benefit in stable coronary artery disease. Eur Heart J Cardiovasc Imaging 2020;21:961–70. https://doi.org/10.1093/ehjci/ jeaa083 727. Doenst T, Bonow RO, Bhatt DL, Falk V, Gaudino M. Improving terminology to describe coronary artery procedures: JACC review topic of the week. J Am Coll Cardiol 2021;78:180–8. https://doi.org/10.1016/j.jacc.2021.05.010 728. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 2018;391:939–48. https://doi.org/10.1016/s0140-6736(18)30423-9 729. Perera D, Clayton T, O’Kane PD, Greenwood JP, Weerackody R, Ryan M, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med 2022;387:1351–60. https://doi.org/10.1056/NEJMoa2206606 730. Sabatine MS, Bergmark BA, Murphy SA, O’Gara PT, Smith PK, Serruys PW, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet 2021;398:2247–57. https://doi.org/10.1016/s0140-6736(21) 02334-5 731. Serruys PW, Ono M, Garg S, Hara H, Kawashima H, Pompilio G, et al. Percutaneous coronary revascularization: JACC historical breakthroughs in perspective. J Am Coll Cardiol 2021;78:384–407. https://doi.org/10.1016/j.jacc.2021.05.024 732. Bangalore S, Maron David J, Stone Gregg W, Hochman Judith S. Routine revascularization versus initial medical therapy for stable ischemic heart disease. Circulation 2020; 142:841–57. https://doi.org/10.1161/CIRCULATIONAHA.120.048194 733. Soares A, Boden WE, Hueb W, Brooks MM, Vlachos HEA, O’Fee K, et al. Death and myocardial infarction following initial revascularization versus optimal medical therapy in chronic coronary syndromes with myocardial ischemia: a systematic review and meta-analysis of contemporary randomized controlled trials. J Am Heart Assoc 2021; 10:e019114. https://doi.org/10.1161/JAHA.120.019114 734. Kumar A, Doshi R, Khan SU, Shariff M, Baby J, Majmundar M, et al. Revascularization or optimal medical therapy for stable ischemic heart disease: a Bayesian meta-analysis of contemporary trials. Cardiovasc Revasc Med 2022;40:42–7. https://doi.org/10.1016/j. carrev.2021.12.005 735. Wang HY, Xu B, Dou K, Guan C, Song L, Huang Y, et al. Implications of periprocedural myocardial biomarker elevations and commonly used MI definitions after left main PCI. JACC Cardiovasc Interv 2021;14:1623–34. https://doi.org/10.1016/j.jcin.2021.05.006 736. Bulluck H, Paradies V, Barbato E, Baumbach A, Bøtker HE, Capodanno D, et al. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2021;42:2630–42. https://doi.org/10.1093/eurheartj/ehab271 737. Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, et al. Myocardial infarction in the ISCHEMIA Trial: impact of different definitions on incidence, prognosis, and treatment comparisons. Circulation 2021;143:790–804. https://doi.org/10.1161/circulationaha.120.047987 738. Redfors B, Stone GW, Alexander JH, Bates ER, Bhatt DL, Biondi-Zoccai G, et al. Outcomes according to coronary revascularization modality in the ISCHEMIA trial. J Am Coll Cardiol 2024;83:549–58. https://doi.org/10.1016/j.jacc.2023.11.002 739. Navarese EP, Lansky AJ, Farkouh ME, Grzelakowska K, Bonaca MP, Gorog DA, et al. Effects of elective coronary revascularization vs medical therapy alone on noncardiac mortality: a meta-analysis. JACC Cardiovasc Interv 2023;16:1144–56. https://doi.org/10. 1016/j.jcin.2023.02.030 740. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail 2017;10:e003875. https:// doi.org/10.1161/circheartfailure.117.003875 741. Panza JA, Chrzanowski L, Bonow RO. Myocardial viability assessment before surgical revascularization in ischemic cardiomyopathy: JACC review topic of the week. J Am Coll Cardiol 2021;78:1068–77. https://doi.org/10.1016/j.jacc.2021.07.004 742. Rahimtoola SH, Dilsizian V, Kramer CM, Marwick TH, Vanoverschelde JL. Chronic ischemic left ventricular dysfunction: from pathophysiology to imaging and its ESC Guidelines 3525 Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026